Cancer Immunology, Immunotherapy

, Volume 64, Issue 1, pp 83–89

Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies

  • Chiara Castelli
  • Licia Rivoltini
  • Monica Rodolfo
  • Marcella Tazzari
  • Cristina Belgiovine
  • Paola Allavena
Focussed Research Review

DOI: 10.1007/s00262-014-1576-1

Cite this article as:
Castelli, C., Rivoltini, L., Rodolfo, M. et al. Cancer Immunol Immunother (2015) 64: 83. doi:10.1007/s00262-014-1576-1

Abstract

Targeted therapies were rationally designed to inhibit molecular pathways in tumor cells critically involved in growth and survival; however, many drugs used in targeted therapies may affect the immune system. In addition, selected conventional chemotherapeutic agents have also been reported to be endowed with direct or indirect effects on immunity, for instance via immunogenic death of tumors. Thus, cancer therapies may have off-target effects, some of which are directed to the immune system. Here, we will review some of these effects in specific therapeutic approaches. We will examine the modulation of the immune contexture in human sarcoma and melanoma induced by anti-angiogenic therapies and by BRAF inhibitors, respectively. We will then discuss how the anti-tumor agent trabectedin is selectively cytotoxic to cells of the monocytic-macrophage lineage and how these immune-related effects can be part of the response to treatment.

Keywords

Targeted therapies Immune responses Tumor-associated myeloid cells Anti-angiogenic therapies BRAF inhibitors NIBIT 2013 

Abbreviations

ASPS

Alveolar soft part sarcoma

DC

Dendritic cells

GIST

Gastrointestinal stromal tumor

M/DSFT

Malignant and dedifferentiated solitary fibrous tumors

M-CSF

Monocyte-colony stimulating factor

MDSC

Myeloid-derived suppressive cells

PDGFR

Platelet-derived growth factor receptor

TAM

Tumor-associated macrophages

TRAIL

Tumor necrosis factor-related apoptosis-inducing ligand

Treg

Regulatory T cells

VEGFR

Vascular endothelial growth factor receptor

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Chiara Castelli
    • 1
  • Licia Rivoltini
    • 1
  • Monica Rodolfo
    • 1
  • Marcella Tazzari
    • 1
  • Cristina Belgiovine
    • 2
  • Paola Allavena
    • 2
  1. 1.Unit of Immunotherapy of Human Tumor, Department of Experimental Oncology and Molecular MedicineFondazione IRCCS Istituto Nazionale dei TumoriMilanItaly
  2. 2.Department of Immunology and InflammationClinical and Research Institute HumanitasMilanItaly

Personalised recommendations